An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 204824
Company: OTTER PHARMS

Products on NDA 204824

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
OTREXUP	METHOTREXATE	10MG/0.4ML (10MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	15MG/0.4ML (15MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	20MG/0.4ML (20MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	25MG/0.4ML (25MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	7.5MG/0.4ML (7.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP	METHOTREXATE	12.5MG/0.4ML (12.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	17.5MG/0.4ML (17.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP	METHOTREXATE	22.5MG/0.4ML (22.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription	None	Yes	Yes
OTREXUP PFS	METHOTREXATE	10MG/0.4ML (10MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP PFS	METHOTREXATE	15MG/0.6ML (15MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP PFS	METHOTREXATE	17.5MG/0.7ML (17.5MG/0.7ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP PFS	METHOTREXATE	20MG/0.8ML (20MG/0.8ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP PFS	METHOTREXATE	22.5MG/0.9ML (22.5MG/0.9ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No
OTREXUP PFS	METHOTREXATE	25MG/ML (25MG/ML)	SOLUTION;SUBCUTANEOUS	Discontinued	None	Yes	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 204824

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/11/2013	ORIG-2	Approval	Efficacy	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204824Orig2s000Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204824Orig1s000,204824Orig2s000_replace_ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig2s000TOC.cfm
10/11/2013	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204824Orig1s000Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204824Orig1s000,204824Orig2s000_replace_ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
12/26/2019	SUPPL-10	Labeling-Patient Package Insert, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/204824Orig1s010ltr.pdf
06/19/2019	SUPPL-9	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/204824Orig1s009ltr.pdf
03/15/2018	SUPPL-8	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204824s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/2018/204824Orig1s008ltr.pdf
05/31/2017	SUPPL-6	Manufacturing (CMC)-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204824s006lbl.pdf
01/11/2017	SUPPL-5	Manufacturing (CMC)		Label is not available on this site.
03/24/2016	SUPPL-4	Manufacturing (CMC)	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204824s004lbl.pdf
11/07/2014	SUPPL-3	Manufacturing (CMC)	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204824s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204824Orig1s003ltr.pdf
10/08/2014	SUPPL-2	Manufacturing (CMC)		Label is not available on this site.
10/07/2014	SUPPL-1	Manufacturing (CMC)		Label is not available on this site.

Labels for NDA 204824

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
12/26/2019	SUPPL-10	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s010lbl.pdf
12/26/2019	SUPPL-10	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s010lbl.pdf
06/19/2019	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s009lbl.pdf
03/15/2018	SUPPL-8	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204824s008lbl.pdf
05/31/2017	SUPPL-6	Manufacturing (CMC)-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204824s006lbl.pdf
03/24/2016	SUPPL-4	Manufacturing (CMC)	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204824s004lbl.pdf
11/07/2014	SUPPL-3	Manufacturing (CMC)	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204824s003lbl.pdf
10/11/2013	ORIG-2	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204824Orig2s000Lbl.pdf
10/11/2013	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204824Orig1s000Lbl.pdf

Top